Evidence map›Paper›PMID 30025128›Full record

ArticleInvestigative ophthalmology & visual science2018

Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) of Macular Pigment.

Lydia Sauer, Karl M Andersen, Binxing Li, Rebekah H Gensure, Martin Hammer, Paul S Bernstein

Open access · goldAbstract readComparative Study
In one paragraph

Article in Investigative ophthalmology & visual science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Macular telangiectasia type 2: An update.The Journal of international medical research · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Review
  10. Review
  11. Detection sensitivity of fluorescence lifetime imaging ophthalmoscopy for laser-induced selective damage of retinal pigment epithelium.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Article
  12. Multispectral label-freeJournal of biomedical optics · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Lydia SauerJohn A. Moran Eye Center, University of Utah, Salt Lake City, Utah, United States.
Karl M AndersenJohn A. Moran Eye Center, University of Utah, Salt Lake City, Utah, United States.
Binxing LiJohn A. Moran Eye Center, University of Utah, Salt Lake City, Utah, United States.
Rebekah H GensureJohn A. Moran Eye Center, University of Utah, Salt Lake City, Utah, United States.
Martin HammerDepartment of Experimental Ophthalmology, University Hospital Jena, Jena, Germany.
Paul S BernsteinJohn A. Moran Eye Center, University of Utah, Salt Lake City, Utah, United States.
University of Utah · USCommonwealth Medical College · USJena University Hospital · DE

Funding

University of Utah, Core Vision Research GrantP30EY014800 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Bryan William Jones · 2005 to 2026
$14.6M
Biochemistry and Pharmacology of the Macular CarotenoidsR01EY011600 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI BERNSTEIN, PAUL STEVEN · 2004 to 2025
$7.7M
BIOCHEMISTRY AND PHARMACOLOGY OF THE MACULAR CAROTENOIDSR29EY011600 · NEI · UNIVERSITY OF UTAH · PI BERNSTEIN, PAUL STEVEN · 1997 to 2001
$209k
NEI NIH HHS P30 EY014800NEI NIH HHS R01 EY011600NEI NIH HHS R29 EY011600
6 · The paper itself

Abstract

Purpose: To describe different patterns of macular pigment (MP) seen in fluorescence lifetime imaging ophthalmoscopy (FLIO) and to analyze ex vivo fluorescence characteristics of carotenoids. Methods: A total of 31 eyes of young healthy subjects, 4 eyes from patients with albinism, 36 eyes with macular telangiectasia type 2 (MacTel), 24 eyes with retinitis pigmentosa, and 1 eye with a macular hole were included in this clinic-based, cross-sectional study. All subjects underwent Heidelberg Engineering FLIO and MP measurements (dual-wavelength autofluorescence). Fundus autofluorescence (FAF) lifetimes of a 30° retinal field were detected in two spectral channels (SSC: 498-560 nm; LSC: 560-720 nm), and amplitude-weighted mean fluorescence lifetimes (τm) were calculated. Additionally, autofluorescence lifetimes of known dilutions of lutein and zeaxanthin were measured in a cuvette in free- and protein-associated states. Results: MP shows a significant inverse correlation to foveal FAF lifetimes measured with FLIO (SSC: r = -0.608; P < 0.001). Different distribution patterns can be assigned to specific disease-related changes. Two patients with albinism, who did not have MP, were found to be missing short FAF lifetimes. In solvent, lutein and zeaxanthin show very short autofluorescence lifetimes (∼50-60 ps; SSC), as do their respective binding proteins (∼40-50 ps; SSC). When combining carotenoids with their specific binding proteins, the decay times shift to longer means (∼70-90 ps; SSC). Conclusions: This study expands upon previous findings of an impact of MP on short FAF lifetimes by describing ex vivo autofluorescence lifetimes of carotenoids and different in vivo autofluorescence patterns that can be associated with certain diseases.

Indexed as

AdultAgedAlbinism, OcularCross-Sectional StudiesFemaleHumansLuteinMacular PigmentMaleMiddle AgedOphthalmoscopyOptical ImagingRetinaRetinal PerforationsRetinal TelangiectasisRetinitis PigmentosaLuteinMacular PigmentZeaxanthins

Identifiers

PMID30025128
PMCPMC6009392
OpenAlexW2883529321

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.